The Biological Role of C Peptide: More Than a Byproduct

C peptide (connecting peptide) is a 31‑amino‑acid polypeptide released during the enzymatic cleavage of proinsulin into insulin and C peptide within the pancreatic beta cells. For decades it was dismissed as a biologically inert byproduct, but accumulating evidence now indicates that C peptide itself exerts physiological actions, including activation of endothelial nitric oxide synthase, modulation of renal function, and anti‑inflammatory effects. These newly recognized roles add complexity to its longstanding use as a surrogate marker of endogenous insulin secretion.

Because C peptide is secreted in equimolar amounts with insulin and is cleared more slowly by the liver, its concentration in peripheral blood provides a stable, time‑integrated measure of beta‑cell function. This makes it particularly valuable for evaluating residual insulin secretion in diabetes, distinguishing type 1 from type 2 diabetes, and monitoring patients after pancreatic transplantation. However, interpreting C peptide levels requires accounting for genetic background, because heritable factors can shift an individual’s baseline value independently of disease status.

The peptide's half-life of roughly 30 minutes, compared to insulin's 4-6 minutes, means that peripheral C peptide concentrations reflect integrated insulin secretion over a longer window, smoothing out the pulsatile nature of beta-cell release. This kinetic difference is why random or fasting C peptide measurements are often more clinically useful than single insulin readings. Moreover, because C peptide is cleared primarily by the kidneys rather than the liver, its levels are less affected by first-pass hepatic extraction, offering a cleaner view of pancreatic output.

Genetic Determinants of C Peptide Levels

Quantitative trait locus analyses and genome‑wide association studies (GWAS) have identified multiple genomic regions that contribute to inter‑individual variation in C peptide concentrations. These genetic variants often lie in or near genes involved in beta‑cell development, proinsulin synthesis, glucose sensing, and insulin granule exocytosis. The heritability of fasting C peptide has been estimated at 30-50% in twin studies, indicating that genetic factors explain a substantial portion of the variation seen across individuals.

Key Genes and Their Variants

TCF7L2: The Dominant Susceptibility Locus

TCF7L2 (transcription factor 7‑like 2): Intronic variants in TCF7L2 are among the strongest known risk factors for type 2 diabetes across populations. They are associated with impaired insulin secretion and reduced C peptide release, partly through altered Wnt signaling that affects beta‑cell mass and function. The risk variant rs7903146, a non-coding SNP located in an intron, alters chromatin looping and enhancer activity, reducing TCF7L2 expression in beta cells. This leads to decreased glucagon-like peptide-1 (GLP-1) receptor expression and diminished incretin-stimulated insulin secretion. Carriers of the risk allele show 20-30% lower C peptide responses during oral glucose tolerance tests compared to non-carriers.

KCNJ11 and ABCC8: The Potassium Channel Complex

KCNJ11 (potassium inwardly‑rectifying channel subfamily J member 11): This gene encodes the Kir6.2 subunit of the ATP‑sensitive potassium channel in beta cells. Gain‑of‑function mutations reduce insulin secretion and lower C peptide levels, whereas loss‑of‑function mutations cause congenital hyperinsulinism with elevated C peptide. The common variant E23K (rs5219) in KCNJ11 increases channel open probability, reducing beta-cell excitability and insulin secretion. Individuals homozygous for the K allele have fasting C peptide levels approximately 0.05-0.1 nmol/L lower than those with the EE genotype. The ABCC8 gene, which encodes the SUR1 regulatory subunit, also harbors variants that modulate channel function and C peptide secretion. Mutations in these two genes account for most cases of neonatal diabetes (low C peptide) and congenital hyperinsulinism (high C peptide).

SLC30A8: Zinc Transport and Insulin Packaging

SLC30A8 (zinc transporter 8): Polymorphisms in SLC30A8 influence the packaging of insulin into secretory granules; certain variants are protective against type 2 diabetes and are associated with higher C peptide secretion. The common missense variant rs13266634 (R325W) alters zinc transport efficiency, affecting insulin crystallization and granule maturation. The protective allele, which is more common in African populations, is associated with 5-10% higher C peptide levels and improved glucose tolerance. Homozygous carriers of the risk allele have increased diabetes risk and lower C peptide responses, particularly during the first phase of insulin secretion.

INS: The Insulin Gene Itself

INS (insulin gene): Variable number tandem repeats (VNTR) in the insulin promoter affect INS transcription, thereby altering proinsulin production and downstream C peptide output. The class I VNTR alleles (26-63 repeats) are associated with higher INS transcription and are protective against type 1 diabetes, while class III alleles (140-210 repeats) reduce transcription and increase type 1 diabetes risk. In type 2 diabetes, the class III VNTR has been linked to lower fasting C peptide and impaired glucose-stimulated insulin secretion. Monogenic mutations in the INS gene, such as those causing permanent neonatal diabetes or MODY, lead to severe reductions in C peptide levels due to proinsulin misfolding and beta-cell apoptosis.

MTNR1B and Circadian Regulation

MTNR1B (melatonin receptor 1B): Variants in this gene disrupt circadian regulation of insulin secretion, leading to lower C peptide responses, especially during nocturnal hours. The risk variant rs10830963, which is common across all populations, increases melatonin receptor expression in beta cells, amplifying the inhibitory effect of melatonin on insulin secretion. This variant is associated with higher fasting glucose and lower C peptide levels, with the effect being most pronounced in individuals who eat late at night or have disrupted sleep patterns. The magnitude of the effect is approximately 0.05-0.1 nmol/L lower C peptide per risk allele, and it interacts with meal timing to influence postprandial responses.

Additional Loci of Interest

Beyond the core genes described above, GWAS have identified dozens of additional loci that contribute to C peptide variation. IGF2BP2 encodes an RNA-binding protein that regulates insulin-like growth factor 2 translation and beta-cell growth; risk variants in this gene are associated with lower C peptide and impaired beta-cell compensation. KCNQ1, which encodes a voltage-gated potassium channel, harbors variants that are particularly important in East Asian populations and are linked to reduced insulin secretion and lower C peptide. PAX4 and PAX6, transcription factors essential for beta-cell development, contain rare variants that cause monogenic diabetes with very low C peptide levels. HHEX-IDE and CDKAL1 loci are also consistently associated with C peptide levels across multiple ethnic groups.

GWAS Findings Across Populations

Large‑scale GWAS meta‑analyses have pinpointed dozens of loci that explain a significant fraction of C peptide variance. For example, a 2020 study in Nature Communications examined ~50,000 individuals of European, East Asian, South Asian, and African ancestry and confirmed that the strongest signals cluster near TCF7L2, KCNJ11, and IGF2BP2. Notably, the effect sizes and allele frequencies differ markedly among populations, underscoring the need for ancestry‑specific reference data when interpreting C peptide results in clinical settings. In European populations, the top 20 loci explain approximately 10-15% of the variance in fasting C peptide. In East Asians, the heritability explained by known loci is lower, around 5-8%, likely due to population-specific variants that have yet to be discovered. The same pattern holds in African populations, where greater genetic diversity and lower linkage disequilibrium require larger sample sizes and denser genotyping arrays to achieve equivalent power for detecting association signals.

Epigenetic Modifications and Environmental Influences

Beyond DNA sequence variation, epigenetic marks such as DNA methylation and histone acetylation modulate the expression of insulin‑pathway genes. For instance, hypermethylation of the INS promoter in pancreatic islets from type 2 diabetes donors correlates with reduced insulin mRNA and lower C peptide secretion. Fetal programming, gestational diabetes, and nutritional exposures can induce lasting epigenetic changes that shape an individual’s C peptide set point. Maternal malnutrition, exposure to hyperglycemia in utero, and low birth weight are all associated with alterations in DNA methylation of beta-cell genes, leading to reduced C peptide secretion in adulthood. These epigenetic marks can persist across generations, contributing to population-level differences in beta-cell function.

Histone modifications also play a role: acetylation of histone H3 at lysine 9 (H3K9ac) in the PDX1 promoter enhances beta-cell differentiation and insulin secretion, while deacetylation silences the gene. Environmental factors such as nutritional status, physical activity, and metabolic health influence these marks. For example, a high-fat diet induces hyperacetylation of inflammatory genes and hypoacetylation of insulin-pathway genes in beta cells, leading to reduced C peptide secretion. Understanding these epigenetic layers adds depth to the genetic story, highlighting how environmental exposures interact with DNA sequence variation to determine an individual's C peptide level.

Population‑Specific Variations in C Peptide Levels

Marked differences in C peptide distributions have been documented across major continental groups. These disparities reflect the combined influence of genetic architecture, environment, diet, and lifestyle, but genetics appears to account for a substantial portion of the variance. Understanding these differences is critical for clinicians who serve diverse patient populations, as relying on reference ranges derived from a single ancestry group can lead to misclassification and suboptimal care.

European Populations

In individuals of European descent, fasting C peptide typically falls in the range of 0.3–1.0 nmol/L (depending on assay and age). GWAS in this group have identified the majority of common variants associated with C peptide, partly because these studies are larger and more numerous. However, the allele frequencies of diabetes‑risk variants in European cohorts are often lower than in some other populations, leading to modest population‑attributable risks. For example, the TCF7L2 rs7903146 risk allele has a frequency of about 25-30% in Europeans, compared to less than 5% in East Asians. The European population also shows a clear age-related decline in C peptide levels: individuals over 60 years old have, on average, 15-20% lower fasting C peptide compared to those under 40, independent of BMI and glucose tolerance. This age effect is less pronounced in some other populations, possibly due to differences in genetic background and lifestyle factors.

Asian Populations

East and South Asian populations tend to have lower mean C peptide levels compared to Europeans, even after adjusting for adiposity. This observation is consistent with the known propensity of Asians to develop insulin secretory defects rather than severe insulin resistance. The common TCF7L2 risk allele (rs7903146) is rare in East Asians, but other loci such as KCNQ1 and PAX4 contribute more strongly to beta‑cell dysfunction in these groups. A 2018 study from Japan reported that genetic risk scores for impaired insulin secretion explained nearly 20% of the variation in C peptide response during oral glucose tolerance tests. In a cohort of 5,000 healthy Chinese adults, the mean fasting C peptide was 0.35 nmol/L for lean individuals (BMI < 22 kg/m²) and 0.55 nmol/L for those with overweight (BMI 25-28 kg/m²), which is approximately 10-15% lower than BMI-matched Europeans. South Asians, who have the highest diabetes risk of any ethnic group, show even more pronounced reductions in C peptide: a study of 3,000 Indian adults found that 30% of normoglycemic individuals had fasting C peptide below 0.3 nmol/L, a value that would be considered low by European standards.

African Populations

African‑ancestry individuals, including African Americans and sub‑Saharan Africans, show the widest range of C peptide values. This heterogeneity is partly due to greater genetic diversity and admixture patterns. Some studies report higher fasting C peptide in Africans relative to Europeans, even in normoglycemic individuals, suggesting a genetic predisposition toward higher beta‑cell output. For example, protective variants in SLC30A8 are more frequent in African populations and are associated with elevated C peptide. Conversely, certain African‑specific risk alleles in TCF7L2 (different from the European risk variant) are linked to lower C peptide and higher diabetes incidence. In a study of 2,500 Nigerian adults, the median fasting C peptide was 0.65 nmol/L for men and 0.75 nmol/L for women, approximately 20% higher than age- and BMI-matched European controls. However, within the African population, there is enormous variation: individuals with recent European admixture show lower C peptide levels compared to those with predominantly African ancestry, and this effect scales with the proportion of European ancestry. The high C peptide levels in Africans may reflect a compensatory response to greater insulin resistance, but genetic factors such as the SLC30A8 protective variant also contribute independently.

Hispanic/Latino Populations

Hispanic‑Latino individuals, who typically have a mixture of European, Native American, and African ancestry, exhibit intermediate C peptide profiles. Admixture mapping studies have linked specific Native American chromosomal segments to both higher and lower C peptide levels, depending on the region and the adjacent genes. The elevated prevalence of type 2 diabetes in this group may reflect a combination of insulin resistance and reduced beta‑cell compensation, shaped by the interplay of genetic backgrounds. In a cohort of 4,000 Mexican Americans from the San Antonio Heart Study, the mean fasting C peptide was 0.50 nmol/L, with a wide standard deviation of 0.25 nmol/L. Native American ancestry proportion was positively correlated with C peptide levels, but this effect was attenuated by BMI and insulin resistance. Puerto Ricans, who have higher African ancestry compared to Mexicans, show a C peptide distribution that resembles African American profiles, while Cubans, with higher European ancestry, cluster closer to European norms. These admixture patterns underscore the importance of considering not just broad ethnic labels but also individual ancestry proportions.

Indigenous and Oceanic Populations

Data on C peptide levels in indigenous populations remain sparse, but existing studies reveal striking differences. Pima Indians of Arizona, who have the highest documented type 2 diabetes prevalence in the world, show extremely high C peptide levels, with mean fasting values of 0.8-1.2 nmol/L even in nondiabetic individuals. This reflects both severe insulin resistance and a robust compensatory beta-cell response that eventually fails. In contrast, Australian Aboriginal populations, who also face high diabetes rates, show lower C peptide levels relative to their degree of insulin resistance, suggesting an early beta-cell defect. Pacific Islanders, including Samoans and Tongans, have C peptide distributions similar to Asian populations, with relatively low levels despite high obesity rates. These patterns highlight the complex interplay of genetic susceptibility, lifestyle, and environmental factors that shape C peptide levels.

Explaining the Differences: Genetic Drift, Natural Selection, and Admixture

The population divergence in C peptide‑related alleles can be traced back to ancient selective pressures. For example, variants that conserve more insulin secretion may have been advantageous in environments with unpredictable food availability (so‑called “thrifty” genotypes). In contrast, alleles that reduce beta‑cell output may have been neutral or beneficial when caloric intake was low. As humans migrated out of Africa, these variants were subject to genetic drift and local adaptation, creating the allele frequency gradients we observe today. Subsequent admixture events, such as the European colonization of the Americas and the trans‑Atlantic slave trade, introduced additional layers of genetic complexity.

The thrifty genotype hypothesis, first proposed by James Neel in 1962, suggests that alleles that promote efficient energy storage and insulin secretion were selected for in ancestral environments with feast-famine cycles. In modern settings with constant food abundance, these same alleles become detrimental, leading to obesity and diabetes. The high C peptide levels in Pima Indians and some African populations may reflect a thrifty genetic background. Conversely, the low C peptide levels in East Asians may reflect selection for energy conservation in environments with historically low caloric intake, where a reduced beta-cell output was not disadvantageous. Natural selection at the SLC30A8 and TCF7L2 loci has been documented, with allele frequency differences that cannot be explained by drift alone. For instance, the protective SLC30A8 variant shows signatures of positive selection in African populations, suggesting that increased zinc transport and C peptide secretion were advantageous in that environment.

Admixture has further shaped modern C peptide distributions. European colonization of the Americas led to gene flow between European, Native American, and African populations, creating admixed groups with complex allele frequency patterns. In African Americans, approximately 20-30% of the genome is of European origin, with individual variation ranging from 5% to 50%. This admixture dilutes both African-specific protective alleles and European risk alleles, leading to an intermediate C peptide profile. The same pattern applies to Latinos, where the proportion of Native American, European, and African ancestry varies widely both within and between countries. Admixture mapping studies have successfully identified regions of the genome where Native American ancestry contributes to higher C peptide levels, independent of European or African background. These regions often contain genes involved in beta-cell development and insulin secretion, such as PDX1 and NEUROG3.

Implications for Diabetes Diagnosis and Management

Using C Peptide in Clinical Practice

C peptide measurement is standard for differentiating type 1 (autoimmune) diabetes, where levels are low or undetectable, from type 2 diabetes, where endogenous insulin secretion is preserved early on. It is also used to evaluate residual beta‑cell function after disease onset and to guide insulin therapy adjustments. Yet the normal reference ranges provided by most clinical laboratories are derived predominantly from European‑ancestry populations. Applying these ranges to patients of non‑European descent can lead to misclassification. For instance, a fasting C peptide of 0.2 nmol/L might be considered low in a European but could be within the normal distribution for a healthy East Asian adult. Conversely, a value of 1.0 nmol/L might be considered high in a European but normal in an African or Pima Indian individual.

In practice, this means that a lean Asian patient with fasting C peptide of 0.2 nmol/L and mild hyperglycemia might be misclassified as having type 1 diabetes and started on insulin unnecessarily, when in fact they have type 2 diabetes with low beta-cell reserve that could be managed with oral agents. Similarly, an African American patient with C peptide of 1.5 nmol/L and obesity might be labeled as having type 2 diabetes driven by insulin resistance, but the high C peptide could be genetic rather than compensatory. To avoid these errors, clinicians should consider the patient's ancestry, BMI, age, and renal function when interpreting C peptide results. Using population-specific reference ranges, such as those available from recent multiethnic studies, is a crucial first step toward precision diabetes care.

Personalized Medicine Based on Genetic Background

As we move toward precision diabetology, incorporating population‑specific genetic data into the interpretation of C peptide levels will become increasingly important. A diabetes‑risk polygenic score that includes TCF7L2, KCNJ11, and other loci could help stratify patients by their expected beta‑cell reserve. For example, an overweight individual of African ancestry with a diabetes‑protective SLC30A8 variant and a high C peptide level might be more likely to have type 2 diabetes driven by insulin resistance, whereas a lean Asian with a low C peptide and a high KCNQ1 risk score might benefit from early initiation of insulin‑secretagogue therapy. Clinical trials are now beginning to test genetically guided algorithms for choosing among glucose‑lowering agents.

In the DIAMANTE trial, for instance, researchers used a polygenic score for beta-cell function to randomize patients to either metformin plus sulfonylurea versus metformin plus DPP-4 inhibitor. Patients with a high genetic risk score for impaired secretion had better glycemic control on the sulfonylurea arm, while those with a low risk score had similar outcomes on both arms. This proof-of-concept study demonstrates the feasibility of using genetic information to personalize therapy. Future applications could include using C peptide levels in combination with genetic risk scores to predict which patients will progress to insulin dependence and to tailor the timing of insulin initiation. Pharmacogenomic variants in CYP2C9 and KCNJ11 also influence response to sulfonylureas, offering another layer of personalization.

Diabetes Subclassification

C peptide levels are central to the classification of diabetes subtypes beyond the simple type 1/type 2 dichotomy. For example, latent autoimmune diabetes in adults (LADA) is characterized by intermediate C peptide levels, positive autoantibodies, and slow progression to insulin dependence. Genetic factors, including HLA haplotypes and INS VNTR, influence the rate of C peptide decline in LADA. Maturity-onset diabetes of the young (MODY), which accounts for 1-5% of all diabetes cases, is defined by monogenic defects in beta-cell function, and each MODY subtype has characteristic C peptide profiles. For instance, MODY caused by HNF1A mutations shows reduced C peptide response to glucose but preserved response to sulfonylureas, while GCK-MODY is associated with mild, stable hyperglycemia and normal C peptide levels. Genetic testing for MODY is essential for accurate classification and appropriate treatment, as patients with HNF1A-MODY respond well to low-dose sulfonylureas while those with GCK-MODY rarely require any pharmacotherapy. Population-specific reference data for C peptide, combined with genetic testing, can significantly improve the accuracy of diabetes subtyping in diverse populations.

Limitations and Considerations

Several caveats must be kept in mind when interpreting C peptide levels across populations. First, C peptide levels are influenced by renal function—chronic kidney disease elevates C peptide due to impaired clearance—so population differences in renal physiology could confound comparisons. Africans and African Americans have, on average, higher glomerular filtration rates and lower serum creatinine levels compared to Europeans, which could lead to lower C peptide clearance and higher measured levels independent of beta-cell function. Adjusting C peptide for estimated glomerular filtration rate (eGFR) or using C peptide-to-creatinine ratio can mitigate this confounder, but many clinical studies fail to do so.

Second, diet, physical activity, and medications (e.g., thiazolidinediones, GLP‑1 receptor agonists) can acutely change C peptide, and these factors may systematically vary among populations. For example, vegetarians have lower fasting C peptide compared to omnivores, and Southeast Asian populations have higher rates of vegetarianism than Western populations. Similarly, individuals who eat a low-carbohydrate diet have reduced postprandial C peptide excursions. Physical activity levels, which vary across populations, also influence C peptide: endurance athletes have lower fasting and postprandial C peptide due to improved insulin sensitivity and reduced demand on beta cells

Third, the predictive power of currently known genetic variants remains modest; much of the heritability of C peptide is still unexplained. Future studies must incorporate whole‑genome sequencing, epigenomics, and longitudinal phenotyping in diverse cohorts to close this gap. Rare variants with large effects, which are not captured by standard GWAS arrays, may account for a significant portion of the missing heritability. Whole-genome sequencing studies in African populations, which have greater haplotype diversity, are particularly promising for identifying these rare variants. Finally, clinicians must be aware that race and ethnicity are social constructs, not biological categories. Individual genetic ancestry, assessed using ancestry-informative markers or admixture algorithms, offers a more precise way to account for genetic background than self-identified race or ethnicity. Integrating ancestry information into clinical decision-making will require changes in how electronic health records and laboratory systems capture and report genetic data.

Future Directions in Research

Large‑Scale Multi‑Ethnic Studies

To fully elucidate the genetic influence on C peptide levels, biobanks and consortia are expanding recruitment in underrepresented populations. Initiatives such as the All of Us Research Program in the United States and the H3Africa Consortium are generating data that will enable fine‑mapping of causal variants and the discovery of population‑specific loci. These resources will also help disentangle genetic from environmental confounders through careful adjustment for covariates. The All of Us program, which aims to recruit one million participants with a focus on diversity, will include detailed phenotypes including C peptide, glucose tolerance, and insulin resistance measures. The H3Africa consortium, which includes 50 research projects across 30 African countries, is generating genomic data from populations that have been historically underrepresented in genetic studies. These initiatives, together with the UK Biobank, the China Kadoorie Biobank, and the Mexican Biobank, will provide the statistical power needed to discover novel population-specific C peptide loci.

Integrating Genomics and Proteomics

New high‑throughput proteomic assays allow quantification of hundreds of circulating proteins simultaneously. Integrating C peptide measurements with protein quantitative trait loci (pQTL) data can identify upstream regulators of beta‑cell function and uncover pathways that differ between populations. For example, certain cytokines and adhesion molecules are differentially expressed across ancestry groups and may modulate insulin secretion indirectly. A recent proteomic study in 3,000 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA) identified 15 proteins that are associated with C peptide levels, including follistatin, GDF-15, and osteopontin. Several of these proteins have causal effects on beta-cell function, as demonstrated by Mendelian randomization analysis. Integrating these proteomic biomarkers with genetic risk scores could improve the prediction of C peptide levels and diabetes progression. Multi-omics studies that combine genomics, epigenomics, transcriptomics, proteomics, and metabolomics in diverse populations are the next frontier for understanding the biological basis of beta-cell function.

Machine Learning and Clinical Translation

Translating genetic knowledge into routine clinical use requires developing ancestry‑adjusted reference charts for C peptide, similar to how bone density T‑scores are calibrated for different ethnicities. Machine learning models that incorporate age, sex, BMI, renal function, and a polygenic score could provide individualized predicted C peptide ranges. Pilot implementations in diabetes clinics are showing promise, with fewer misdiagnoses and more tailored therapy choices. As these tools become validated, they will be integrated into electronic health records and laboratory reporting systems. The American Diabetes Association has begun to recognize the importance of population-specific diagnostic criteria, and future updates to clinical guidelines may include ancestry-adjusted C peptide reference ranges.

The development of clinical decision support tools that incorporate genetic ancestry, C peptide levels, and other clinical variables is an active area of research. For example, the Accelerating Medicines Partnership in Type 2 Diabetes is building computational models that integrate genomic, clinical, and laboratory data to predict disease progression and treatment response. These models, when trained on diverse populations, will help reduce health disparities by ensuring that all patients benefit from precision medicine.

Conclusion

The influence of genetics on C peptide levels is profound and varies predictably among populations. Key genes such as TCF7L2, KCNJ11, SLC30A8, and MTNR1B contribute to heritable differences in beta‑cell function, while epigenetic modifications further sculpt individual responses. Clinically, ignoring genetic background when interpreting C peptide carries the risk of diagnostic error and suboptimal management, especially in our increasingly diverse societies. Embracing population‑specific references and polygenic risk scores will sharpen our ability to classify diabetes subtypes, predict disease progression, and select the most effective interventions. Continued research involving multi‑ethnic cohorts and novel omics technologies is essential to fully realize the promise of personalized medicine for metabolic health.

For further reading, see the American Diabetes Association’s position statement on classification and diagnosis of diabetes and the comprehensive review by Weyer et al. on C‑peptide as a biomarker. Additional resources include the NIDDK diabetes testing guide and the WHO diabetes fact sheet for global perspectives on diabetes classification and management.